Although we utilized liver lysates to partly support the effect of irisin on the MD2-TLR4 complex in vivo, the therapeutic effect of irisin on NAFLD would need to be confirmed by injection of irisin in NAFLD mice, which remains a limitation of our study. The gene discussed is FNDC5; the disease is metabolic dysfunction-associated steatotic liver disease.